Rheumatology Therapeutics Market to Grow with a CAGR of 5.98% through 2030
Advancements in
targeted therapies and growing healthcare expenditure to improve treatment
accessibility, is expected to drive the Global Rheumatology Therapeutics Market
growth in the forecast period, 2026-2030
According to
TechSci Research report, “Rheumatology Therapeutics Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2030F”,
the Global Rheumatology Therapeutics Market stood at USD 26.11 Billion in
2024 and is expected to reach USD 37.05 Billion by 2030 with a CAGR of 5.98% during
the forecast period. This can be due to
collaborations and partnerships among leading companies with a diverse approach
to merge the expertise of individual companies and to strengthen their position
in the market. Personalized medicine, which tailors’
medical treatment to individual patient characteristics, is a significant
driver of demand in the Global Rheumatology Therapeutics Market. This approach
recognizes that patients with rheumatic diseases, such as rheumatoid arthritis
(RA) and lupus, can have varying disease manifestations, genetic profiles, and
responses to treatment. Personalized medicine allows healthcare providers
to select treatments that are more likely to be effective for a particular
patient based on their unique disease profile. This can lead to better
treatment outcomes, including reduced disease activity, joint damage, and pain.
Advances in genomics and biomarker research have led to the identification of
specific genetic markers and biomarkers associated with rheumatic diseases.
These markers can guide treatment decisions, helping to match patients with the
most appropriate therapies. Personalized medicine aims to minimize the risk of
adverse effects by tailoring treatments to individual patient characteristics.
This is particularly important in rheumatology, where medications can have side
effects, and some patients may be more susceptible than others.
In April 2022, the FDA has authorized RINVOQ for the treatment of people with active ankylosing spondylitis (AS) who have experienced a suboptimal response to or intolerance to one or more tumor necrosis factor (TNF) blockers, according to a statement from AbbVie. Inflammatory back pain, stiffness, and limited mobility are some of the incapacitating symptoms of AS, a chronic inflammatory musculoskeletal illness that primarily affects the spine. Approximately 1.1 million adults in the US, or one out of every 200, are thought to have AS. RINVOQ is a selective JAK inhibitor that was found and created by AbbVie researchers and is currently being researched for use in several immune-mediated inflammatory illnesses. RINVOQ showed stronger inhibitory potency for JAK-1 than JAK-2, JAK-3, and TYK-2.1 in enzymatic and cellular studies. The relationship between the inhibition of JAK enzymes and treatment efficacy and safety is not currently understood.
Biosimilar competition is a significant challenge in the Global Rheumatology Therapeutics Market, as well as in the broader pharmaceutical industry. Biosimilars are biologic drugs that are highly like already approved reference biologics but typically come at a lower cost. One of the primary drivers behind the development and adoption of biosimilars is their potential to reduce the cost of biologic therapies. While this can be advantageous for patients and healthcare systems, it poses a challenge to innovative biologic manufacturers who may face price competition. The availability and adoption of biosimilars can erode the market share of reference biologics. As more biosimilars enter the market, they may capture a significant portion of the patient population, impacting the sales of the originator biologics. Achieving market access and securing favorable reimbursement for biosimilars can be challenging. This can limit the adoption of biosimilars and their ability to compete effectively.
Browse over XX market data Figures and
spread through 110
Pages and an in-depth TOC on "Global Rheumatology Therapeutics Market”
The Global Rheumatology Therapeutics Market is segmented into indication, distribution channel, regional distribution, and company.
Based on the Distribution
Channel, Online Pharmacies emerged as the fastest growing segment in the Global
Rheumatology Therapeutics Market during the forecast period. This is due to increasing digitalization,
convenience, and growing patient preference for doorstep delivery of
medications. The rising adoption of e-commerce platforms, coupled with
advancements in telemedicine, has significantly contributed to the expansion of
online pharmacy services. Patients with chronic rheumatic conditions require
long-term medication, making the subscription-based and home-delivery models of
online pharmacies highly attractive. Additionally, the widespread penetration
of smartphones and the internet has facilitated easier access to online
pharmaceutical platforms, enabling patients to compare prices, access
discounts, and receive expert consultations remotely.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Rheumatology Therapeutics Market during
the forecast period. This is due the increasing presence of multinational
pharmaceutical companies and local players focusing on research and development
in rheumatology therapeutics. Many global pharmaceutical giants are entering
the region through partnerships, joint ventures, and direct investments,
leveraging the growing patient pool and rising healthcare expenditure.
Additionally, local pharmaceutical manufacturers are actively developing
cost-effective biosimilars to cater to the price-sensitive population, making
advanced rheumatology treatments more accessible. The region has also witnessed
a rise in clinical trials and drug approvals for novel rheumatology therapies,
supported by regulatory agencies becoming more proactive in streamlining the
approval process. The rapid urbanization and lifestyle changes in the region
have contributed to the rising incidence of autoimmune disorders, further
fueling market expansion. Moreover, increased investment in telemedicine and
digital healthcare platforms has improved patient outreach and follow-up care,
enhancing treatment adherence rates.
Some of the major companies operating in
the Global Rheumatology Therapeutics Market are:
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Merck & Co., Inc.
- Amgen Inc.
- Novartis AG
- Janssen Pharmaceuticals, Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Johnson & Johnson Private Limited
- F. Hoffmann-La Roche Ltd
Download Free Sample Report
Customers can also request 10% free
customization on this report
“The Global
Rheumatology Therapeutics Market is expanding due to the growing focus on
regenerative medicine, including stem cell therapy and tissue engineering,
which aims to repair damaged joints and modulate immune responses in autoimmune
diseases. Advances in mesenchymal stem cell research have shown potential in
reducing inflammation and promoting cartilage regeneration, offering a
promising alternative to conventional treatments. Additionally, increasing
investments in clinical trials exploring regenerative approaches for rheumatoid
arthritis and osteoarthritis are accelerating the development of
next-generation therapies. As research progresses, regenerative medicine is
expected to complement existing biologic and targeted therapies, further
driving market expansion.,” said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“Rheumatology
Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, Segmented By Indication (Ankylosing Spondylitis, Gout,
Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis), By Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region
and Competition, 2020-2030F”, has evaluated the future growth potential of Global
Rheumatology Therapeutics Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Rheumatology
Therapeutics Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com